Skip to main content
. 2023 Jun 16;325(1):H187–H194. doi: 10.1152/ajpheart.00270.2023

Figure 3.

Figure 3.

A and B: acetylcholine (ACh)-stimulated nitric oxide (NO) production (A; **P < 0.01) and mitochondrial reactive oxygen species (mtROS) bioactivity (B; *P < 0.05) in response to levels of oxidized low-density lipoprotein (oxLDL) measured in plasma from subjects after placebo supplementation (90 ng/mL) or fetal bovine serum (FBS) (n = 6/condition). Independent t tests. C and D: ACh-stimulated NO production (C) and mtROS bioactivity (D) following exposure to plasma with oxLDL normalization (n = 19/condition) and/or lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) antibody blockade (n = 8 or 9/condition; open circles). Data and representative images presented for the placebo plasma and mitochondria-targeted antioxidant (MitoQ) plasma conditions in C and D are the same as those presented in Fig. 1, A and B, respectively, to facilitate comparison of the magnitude of effect of oxLDL addback and LOX-1 blockade. Purple, older men (n = 8); orange, postmenopausal women (n = 11). P < 0.05 compared with *placebo; †MitoQ + oxLDL; and ‡MitoQ. One-way repeated-measures ANOVA. Data are means ± SE.